Lorem Cytori is committed to developing and commercializing specialty therapeutics. In 2019, Lorem Vascular Pte. Ltd. and its subsidiaries (collectively “Lorem Cytori”) acquired the global cell therapy business (excluding Japan) from the former Cytori Therapeutics, Inc. (now Plus Therapeutics, Inc.). Lorem Cytori has been operating the cell therapy business in China, Australia, Singapore, Malaysia and Hong Kong since 2013. Lorem Cytori enables researchers and clinicians to study and administer cell therapies using our novel Celution® System platform which harnesses the potential of stem and regenerative cells from adipose tissue.
Lorem Cytori is dedicated to enhancing lives through the development of advanced medical devices. To realize this mission, Cytori defines, develops, and delivers specialty devices that enable the medical community to address a variety of unmet medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we strive to deliver meaningful results that create exceptional value for patients, customers, partners, employees, shareholders, and society.
- We do what is right, deliver what we promise and own the outcome.
- We place our patients and customers at the heart of everything we do.
- We thoughtfully balance competing priorities to achieve important results.
- We are an agile company that embraces big challenges.
- We value spirited communication and care about one another.
Lorem Cytori has teams of experienced professionals in medical device manufacturing & sales positioned around the world. Our personnel are committed to providing the highest quality medical devices and laboratory equipment to the world.
In 2013, Cytori granted Bimini Technologies a global exclusive license to Cytori Cell Therapy technology for hair applications. Through Kerastem, its wholly owned subsidiary, Bimini Technologies is conducting a FDA-approved, 70 patient, Phase II clinical trial in the U.S. called STYLE. Learn about the 6 month top-line results released in December 2017 here.
In 2019, Lorem Cytori entered into a supply agreement with Cytori KK in Japan for the supply of products for the Japan market.
For parties interested in licensing Cytori Cell Therapy™ products or StemSource laboratory products, please contact us at BusinessDevelopment@cytori.com.